Long intergenic non-coding rna as pancancer biomarker

Patent metadata

Field	Value
Publication number	US-2019249257-A1
Application number	US-201716079490-A
Country	US
Kind code	A1
Filing date	Feb 27, 2017
Priority date	Feb 26, 2016
Publication date	Aug 15, 2019
Grant date	—

Abstract

Certain embodiments of the invention provide a method for identifying a cancer cell, comprising detecting increased Sexpression of at least one lincRNA selected from the group consisting of PCAN-1, PCAN-2, PCAN-3, PCAN-5 and PCAN-6 and/or decreased expression of lincRNA PCAN-4 in a nucleic acid sample derived from the cell, wherein increased expression of at least one of PCAN-1, PCAN-2, PCAN-3, PCAN-5 and PCAN-6 and/or decreased expression of PCAN-4, as compared to expression from a control cell, indicates the cell is a cancer cell.

First claim

1 - 2 . (canceled)

3 . A method for identifying a patient having cancer, comprising detecting increased expression of PCAN-1 in a nucleic acid sample that was derived from a biological sample obtained from the patient, wherein increased expression of PCAN-1, as compared to expression from a control sample, indicates the patient has cancer.

4 - 6 . (canceled)

7 . A method comprising:
1) detecting increased expression of PCAN-1 in a nucleic acid sample that was derived from a biological sample obtained from a patient; 2) diagnosing the patient with cancer when increased expression of PCAN-1 is detected, as compared to expression from a control sample; and 3) administering an effective amount of a therapeutic agent to the patient.

8 - 10 . (canceled)

11 . The method of claim 3 , wherein expression of PCAN-1 is increased by at least about 10%.

12 . The method of claim 7 , wherein expression of PCAN-1 is increased by at least about 10%.

13 - 19 . (canceled)

20 . A method for treating cancer in a patient comprising administering an effective amount of a therapeutic agent to the patient, wherein the cancer was determined to comprise increased expression of PCAN-1, as compared to expression from a control.

21 - 28 . (canceled)

29 . The method of claim 20 , wherein expression of PCAN-1 was increased by at least about 10%.

30 - 34 . (canceled)

35 . The method of claim 3 , wherein the cancer is a breast, head and neck, thyroid, colon, kidney, liver, lung, prostate, gastric, ovarian or endometrial cancer.

36 - 37 . (canceled)

38 . The method of claim 3 , wherein the PCAN-1 expression is detected using reverse transcriptase-polymerase chain reaction (RT-PCR) methods, quantitative real-time PCR (qPCR), microarray, RNA sequencing (RNA-Seq), next generation RNA sequencing (deep sequencing), gene expression analysis by massively parallel signature sequencing (MPSS), or transcriptomics.

39 - 43 . (canceled)

44 . The method of claim 7 , wherein the therapeutic agent is an anti-cancer agent.

45 . The method of claim 7 , wherein the therapeutic agent is a chemotherapeutic agent.

46 - 49 . (canceled)

50 . The method of claim 7 , wherein the therapeutic agent is an antisense nucleic acid selected from the group consisting of siRNA, shRNA, or miRNA.

51 - 57 . (canceled)

58 . The method of claim 7 , wherein the biological sample is a tissue sample or a plasma sample.

59 - 64 . (canceled)

65 . The method of claim 7 , wherein the cancer is a breast, head and neck, thyroid, colon, kidney, liver, lung, prostate, gastric, ovarian or endometrial cancer.

66 . The method of claim 7 , wherein the cancer is breast cancer or lung cancer.

67 . The method of claim 7 , wherein the PCAN-1 expression is detected using reverse transcriptase-polymerase chain reaction (RT-PCR) methods, quantitative real-time PCR (qPCR), microarray, RNA sequencing (RNA-Seq), next generation RNA sequencing (deep sequencing), gene expression analysis by massively parallel signature sequencing (MPSS), or transcriptomics.

68 . The method of claim 20 , wherein the cancer is a breast, head and neck, thyroid, colon, kidney, liver, lung, prostate, gastric, ovarian or endometrial cancer.

69 . The method of claim 20 , wherein the cancer is breast cancer or lung cancer.

70 . The method of claim 20 , wherein the therapeutic agent is an anti-cancer agent.

71 . The method of claim 20 , wherein the therapeutic agent is an antisense nucleic acid selected from the group consisting of siRNA, shRNA, or miRNA.

Assignees

• Univ Hawaii

Inventors

• Ching Travers
• Garmire Lana

Classifications

• C12Q1/6886 Primary

  for cancer (immunoassay for cancer G01N33/575) · CPC title

• C12Q2600/118

  Prognosis of disease development · CPC title

• C12Q2600/158

  Expression markers · CPC title